CD163 and AIDS: In a population of successfully treated individuals living with HIV switching from a triple-drug to a dual-drug regimen as a simplification strategy, we found that sCD163, a well-known marker of macrophage activation (17), increased in patients with a low CD4 nadir, a previous AIDS-defining event or detectable residual viremia during follow-up, despite sustained virological control (18).